CoverageForm 410-K10-Q8-K13D13G13F

TRFE · Trustfeed Corp. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Income Statement

Line itemQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Revenue-$6.2K$14.5K$13.6K-$21.5K---$4.5K
Cost of Revenue-$1.8K$1.6K$10.9K-$985----
Gross Profit-$4.3K$3.8K$2.7K-$8.9K---$4.5K
R&D----------
SG&A-$619.0K$556.7K$398.8K-$256.3K$20.1K$69.0K-$70.7K
Total Operating Expenses-$633.1K$567.2K$418.6K-$268.0K$20.1K$69.0K-$70.7K
D&A---$2.5K------
Operating Income-($628.8K)($563.3K)($415.4K)-($259.2K)($20.1K)($69.0K)-($70.7K)
Interest Expense-$21.0K$42.2K$41.4K-$12.2K----
Income Tax----------
Net Income-($649.8K)($605.6K)($718.8K)-($271.3K)($20.1K)($127.6K)-($108.1K)
EPS - Basic-($0.02)($0.02)($0.02)-($0.01)$0.00($0.00)--
EPS - Diluted-($0.02)($0.02)($0.02)-($0.01)$0.00($0.00)--

Balance Sheet

Line itemQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Cash & Equivalents$132.2K$38.9K$4.7K$129.3K$6.2K$16.2K$294$244$224$4.6K
Accounts Receivable----------
Inventory$93.6K$158.8K$74.4K$70.0K$68.8K$3.5K----
Accounts Payable----------
Current Assets$322.7K$197.7K$93.1K$201.2K$76.8K$156.1K$294$244$244$129.0K
Total Assets$390.0K$9.27M$9.43M$9.81M$9.95M$19.29M$294$244$244$129.0K
Current Liabilities$1.61M$1.50M$1.04M$1.66M$1.34M$953.8K$103.0K$82.8K$13.8K$14.9K
Long-term Debt----------
Total Liabilities$1.61M$1.50M$1.04M$1.67M$1.35M$977.4K$103.0K$82.8K$13.8K$14.9K
Stockholders' Equity($1.22M)$7.77M$8.40M$8.14M$8.60M$18.31M($102.7K)($82.6K)($13.5K)$114.1K
Retained Earnings($13.61M)($4.62M)($3.97M)($3.37M)($2.91M)($2.19M)($1.49M)($1.47M)($1.40M)($1.27M)

Cash Flow

Line itemQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Operating Cash Flow---($164.8K)---($73.0K)--
Investing Cash Flow---($41.5K)------
Financing Cash Flow---$225.4K---$45.7K--
CapEx---$41.5K------
Free Cash Flow---($206.2K)------

Ratios

MetricQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Profitability
Gross margin-70.1%26.4%19.9%-41.3%---100.0%
Operating margin--10203.0%-3886.4%-3052.2%--1207.9%----1561.1%
EBITDA margin----3033.9%------
Net margin--10543.2%-4177.7%-5281.3%--1264.5%----2389.4%
Free cash flow margin----1515.2%------
FCF / Net income---0.29------
R&D / Revenue----------
SG&A / Revenue-10044.3%3840.3%2930.5%-1194.7%---1561.1%
Effective tax rate----------
Return on assets--7.0%-6.4%-7.3%--1.4%-6842.2%-52292.6%--83.9%
Return on equity--8.4%-7.2%-8.8%--1.5%19.6%154.5%--94.8%
Return on invested capital----------
Liquidity
Current ratio0.200.130.090.120.060.160.000.000.028.65
Quick ratio0.140.030.020.080.010.160.000.000.028.65
Cash ratio0.080.030.000.080.000.020.000.000.020.31
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage--30.0x-13.3x-10.0x--21.3x----
Equity multiplier-0.321.191.121.201.161.05-0.00-0.00-0.021.13
Liabilities / Assets4.130.160.110.170.140.05350.25339.3756.490.12
Efficiency
Asset turnover-0.000.000.00-0.00---0.04
Inventory turnover-0.010.020.16-0.28----
Days sales outstanding----------
Days inventory outstanding-31503d16578d2345d-1282d----
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)--71.3%---374.1%----
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)--51.2%---95.8%----
Operating income growth (YoY)--142.6%-2700.4%-501.8%--266.8%77.9%---
Net income growth (YoY)--139.5%-2910.4%-463.3%--150.9%77.9%---
EPS growth (YoY)--100.0%--3233.3%------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)--57.6%---15951.8%----

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Trustfeed Corp. against the 5 most active filers in the same SIC group.